CRVO vs. IMAB, IXHL, GLSI, RGLS, CAPR, RZLT, ACET, KPTI, PRQR, and SCPH
Should you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include I-Mab (IMAB), Incannex Healthcare (IXHL), Greenwich LifeSciences (GLSI), Regulus Therapeutics (RGLS), Capricor Therapeutics (CAPR), Rezolute (RZLT), Adicet Bio (ACET), Karyopharm Therapeutics (KPTI), ProQR Therapeutics (PRQR), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical preparations" industry.
I-Mab (NASDAQ:IMAB) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, community ranking, valuation, media sentiment, analyst recommendations, dividends and earnings.
In the previous week, CervoMed had 1 more articles in the media than I-Mab. MarketBeat recorded 1 mentions for CervoMed and 0 mentions for I-Mab. CervoMed's average media sentiment score of 0.00 beat I-Mab's score of -1.00 indicating that I-Mab is being referred to more favorably in the media.
CervoMed's return on equity of 0.00% beat I-Mab's return on equity.
I-Mab presently has a consensus price target of $12.25, indicating a potential upside of 580.56%. CervoMed has a consensus price target of $57.50, indicating a potential upside of 130.00%. Given CervoMed's higher probable upside, equities research analysts plainly believe I-Mab is more favorable than CervoMed.
38.4% of I-Mab shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 2.0% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
CervoMed has higher revenue and earnings than I-Mab.
I-Mab has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, CervoMed has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.
I-Mab received 53 more outperform votes than CervoMed when rated by MarketBeat users. However, 100.00% of users gave CervoMed an outperform vote while only 62.92% of users gave I-Mab an outperform vote.
Summary
I-Mab beats CervoMed on 9 of the 14 factors compared between the two stocks.
Get CervoMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CervoMed Competitors List
Related Companies and Tools
